Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
N6-methyladenosine–mediated overexpression of long noncoding RNA ADAMTS9-AS2 triggers neuroblastoma differentiation via regulating LIN28B/let-7/MYCN signaling
Yun Liu, Jun Zhang, Fang Cao, Xiaobao Dong, Jie Li, Yanna Cao, Zhanglin Li, Yan Guo, Jie Yan, Yuanyuan Liu, Qiang Zhao
Yun Liu, Jun Zhang, Fang Cao, Xiaobao Dong, Jie Li, Yanna Cao, Zhanglin Li, Yan Guo, Jie Yan, Yuanyuan Liu, Qiang Zhao
View: Text | PDF
Research Article Oncology

N6-methyladenosine–mediated overexpression of long noncoding RNA ADAMTS9-AS2 triggers neuroblastoma differentiation via regulating LIN28B/let-7/MYCN signaling

  • Text
  • PDF
Abstract

Neuroblastomas have shed light on the differentiation disorder that is associated with spontaneous regression or differentiation in the same tumor at the same time. Long noncoding RNAs (lncRNAs) actively participate in a broad spectrum of biological processes. However, the detailed molecular mechanisms underlying lncRNA regulation of differentiation in neuroblastomas remain largely unknown. Here, we sequenced clinical samples of ganglioneuroma, ganglioneuroblastoma, and neuroblastoma. We compared transcription profiles of neuroblastoma cells, ganglion cells, and intermediate state cells; verified the profiles in a retinoic acid–induced cell differentiation model and clinical samples; and screened out the lncRNA ADAMTS9 antisense RNA 2 (ADAMTS9-AS2), which contributed to neuroblastoma differentiation. ADAMTS9-AS2 upregulation in neuroblastoma cell lines inhibited proliferation and metastatic potential. Additional mechanistic studies illustrated that the interactions between ADAMTS9-AS2 and LIN28B inhibited the association between LIN28B and primary let-7 (pri-let-7) miRNA, then released pri-let-7 into cytoplasm to form mature let-7, resulting in the inhibition of oncogene MYCN activity that subsequently affected cancer stemness and differentiation. Furthermore, we showed that the observed differential expression of ADAMTS9-AS2 in neuroblastoma cells was due to N6-methyladenosine methylation. Finally, ADAMTS9-AS2 upregulation inhibited proliferation and cancer stem-like capabilities in vivo. Taken together, these results show that ADAMTS9-AS2 loss leads to malignant neuroblastoma by increasing metastasis and causing dysfunctional differentiation.

Authors

Yun Liu, Jun Zhang, Fang Cao, Xiaobao Dong, Jie Li, Yanna Cao, Zhanglin Li, Yan Guo, Jie Yan, Yuanyuan Liu, Qiang Zhao

×

Figure 4

The lncRNA ADAMTS9-AS2 interacts with LIN28B to inhibit the association between LIN28B and pri-let-7.

Options: View larger image (or click on image) Download as PowerPoint
The lncRNA ADAMTS9-AS2 interacts with LIN28B to inhibit the association ...
(A) Image of an SDS-PAGE gel with silver staining. RNA pulldown was performed using SK-N-Be2 cell lysates. Biotinylated anti-sense probe was used as a control. (B) RIP enrichment was determined by comparing the relative levels of ADAMTS9-AS2 in the immunoprecipitated LIN28B with the IgG control, with 18S rRNA serving as an internal standard (n = 3). (C) Biotinylated ADAMTS9-AS2 was incubated with SK-N-Be2 cell lysate and then isolated using streptavidin-conjugated beads. Western blotting was conducted to evaluate the expression of LIN28B in both cell lysate input and RNA pulldown; biotinylated anti-sense ADAMTS9-AS2 was used as the control. (D) Pri-let-7 expression levels decreased and mature let-7 accumulated following transient ADAMTS9-AS2 expression. Accumulation of pri-let-7 and decrease in let-7g expression using transient siADAMTS9-AS2 in IMR-32 and SK-N-Be2 cells detected by qRT-PCR (n = 3). (E) RIP was performed to examine the relative levels of pri-let-7g and pri-let-7a-1 in the immunoprecipitates of LIN28B and compared with IgG control in the transient ADAMTS9-AS2 and pcDNA3.1+ cells (n = 3). (F) Binding of ADAMTS9-AS2 to Flag-tagged CSD-NLS, ZKD-NLS, and CSD-NLS-ZKD-NLS as determined using the RIP assay (n = 3). (G and H) ADAMTS9-AS2 was knocked down or overexpressed in SK-N-Be2 and IMR-32 cells. The levels of ADAMTS9-AS2, LIN28B, MYCN, and pluripotency transcription factors SOX2, OCT4, and NANOG were detected using qRT-PCR (n = 3). Immunoblots of MYCN, SOX2, OCT4, LIN28B, and β-actin were examined. Horizontal dotted lines separate blots on different gels. Experiments were conducted in triplicate and data are presented as mean ± SD. Statistical differences were calculated using unpaired 2-sided Student’s t test except for multiple-group comparisons for which 1-way ANOVA was used. *P < 0.05; ***P < 0.001; ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts